Competitive Technologies, Inc. (CTT) - 500 Beiträge pro Seite

[panik]

Profile:Competitive Technologies, Inc. and its subsidiaries provide technology transfer, selling, and licensing services worldwide. The company identifies and commercializes, or finds companies that commercialize for it, technologies in life and physical sciences, electronics, and nanotechnologies. Life sciences include medical testing, diagnostics, pharmaceuticals, biotechnologies, medical devices, and other medical or biological applications. Physical sciences include chemical, display, and environmental applications. Electronics include communications, semiconductors, Internet related, e-commerce, and consumer electronics applications. Nanotechnologies deal with the manipulation of microscopic particles into useful arrangements, and smart or novel materials. The company was founded in 1968 and is based in Fairfield, Connecticut.


http://www.competitivetech.net/

[panik]

Competitive Technologies Signs Marketing Agreement for Solar Panel Technology
Monday November 26, 3:20 pm ET


FAIRFIELD and AVON, Conn., Nov. 26, 2007 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT - News) and Articulated Technologies, LLC today announced that they have signed an agreement for CTT to license and commercialize Articulated's patented organic light emitting diode (OLED) technology for adaptation to solar power. The agreement provides for revenue sharing between CTT and Articulated of royalty and licensing payments.

``CTT is positioning itself at the forefront of the paradigm shift in both energy and healthcare,'' said John B. Nano, CTT's Chairman, President and CEO. ``The current environment of record-high costs in both energy and healthcare has driven CTT's strategy of exploiting the resulting dynamic opportunities. We are capitalizing on our contacts and broadening our base of innovative technologies that fulfill these opportunities. Articulated's portfolio of approximately 40 issued and pending patents fulfills those needs for alternative energy. The U.S. Department of Energy estimates that the Sun delivers more energy in one hour than the Earth's inhabitants use in one year. This portfolio of technologies allows us to put that energy to cost-effective and environmentally-friendly use.''

John Daniels, Founder and Chairman of Articulated, said, ``We believe this relationship allows us to move forward with the development and commercialization of our break-through technologies for use in solar panel applications.''

In addition to the solar panel technology, Articulated is the innovative leader in logical, yet truly disruptive, technologies for roll-to-roll LED solid state lighting, OLED manufacturing, and device structures of thin film, flexible, light emissive materials in ILED (Inorganic Light Emitting Diodes) and OLED applications. These applications include lighting, signage, displays, and backlighting, and medical, automotive, architectural and safety products. Articulated also holds IP on new methods of packaging microelectronics and semiconductors, and on printed electronics.

Paul Levitsky, President and CEO of Articulated, said, ``We are looking forward to working with CTT to bring our patented technologies to market and create revenue opportunities for both companies. The technology satisfies an important growing development in today's society for cost-effective clean energy.''

Mr. Nano added, ``This new solar panel adaptable technology, together with the group of LED technologies currently in our portfolio, further strengthens our ability to fulfill the demand for energy efficient technologies. We are also aggressively marketing technologies that embrace today's shift in the healthcare market, integrating the traditional and holistic methods of treating illness and pain. In addition to the MC Square stress reduction device (http://www.relaxmc.com), we are marketing our pain management therapy, UAD tubular-connection, bone biomaterial, and Lupus diagnostic and monitoring to drive revenue growth, improve profitability and create shareholder value. Our full technology portfolio may be viewed on our website.''

About Articulated Technologies, LLC

Articulated Technologies, LLC, based in Avon, CT, is a dynamic, growing company focused on the development of logical, yet truly disruptive, new manufacturing technologies and methods, and device structures that span a diverse set of OLED solar, OLED and LED lighting, displays, printed electronics, backlighting, and LED solid state lighting solutions. Visit Articulated's website: http://www.articulux.com

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: http://www.competitivetech.net

Statements about our future expectations are ``forward-looking statements'' within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words ``may,'' ``will,'' ``should,'' ``anticipate,'' ``believe,'' ``appear,'' ``intend,'' ``plan,'' ``expect,'' ``estimate,'' ``approximate,'' and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in Item 1A under the caption ``Risk Factors,'' in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, being filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.



Contact:
IR Services, LLC, for CTT
Johnnie D. Johnson
860 434 2465
[e-mail]

Articulated Technologies, LLC
Edward Crofton
860 269 3270
[e-mail]


--------------------------------------------------------------------------------
Source: Competitive Technologies, Inc.

[50bager]

eine noch unentdeckte solar aktie

[lerchengrund]

endlich ein neuer threat.


endlich tut sich mal was in der Aktie !!!

[lerchengrund]

Competitive Technologies and Daeyang E&C Launch Pain Management Technology in Korea
FAIRFIELD, Conn., Nov. 29, 2007 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT) announced today at a media event in Seoul, Korea that together with licensee Daeyang E&C, Co., Ltd. (KOSDAQ:033030) they have launched the worldwide commercialization program for CTT's pain management therapy. The therapy device, from the research of CTT client Professor Giuseppe Marineo of Delta Research & Development in Rome, treats oncological and neuropathic pain that has proven resistant to traditional drug protocols. CTT coordinated with Professor Giancarlo Elia Valori, President of the Italian economic development group, Sviluppo Lazio, on its agreement for license rights to the pain management therapy. A multi-processor device shipped from Italy to Korea was used to treat patients in a demonstration at today's event for about 50 television and print media representatives. This device will be utilized to develop commercial production in Korea for worldwide distribution.


CTT's agreement with Korea-based Daeyang is for the production of the therapy's multi-processor device for worldwide sales. Daeyang will invest about $1 million for re-design and tooling, placing the technology algorithms within the system operating chips, to produce a sleeker, smaller, fully commercial product for institutional and home markets. The agreement provides equally shared profits between CTT and Daeyang in a new CTT business model to increase profit margins.

Young Hyun Lim, Daeyang's CEO, said, "We are confident about working with CTT to bring this patented technology to commercialization in the worldwide pain management market. Daeyang has successfully created and marketed similar products with sales exceeding 1.5 million units, valued at over $500 million."

"CTT's business model in this agreement allows the company to move beyond our usual royalty arrangement and share in the profits of manufacturing and distribution as well," said John B. Nano, CTT's Chairman, President and CEO. "Launching commercialization of this important device is another example of a CTT technology being at the forefront of the paradigm shift to treat individuals with biophysical as well as biochemical methods. It is estimated that the pain management market is growing by 30% per year, and will reach $40 billion by 2010. Worldwide, the high cost for healthcare has led to a re-examination of treatment processes. This has lead to the integration of traditional and holistic medical methods for treating illness and pain, resulting in the inclusion of biophysical treatment methodologies. Two of CTT's important technologies, this pain management therapy and our MC Square device for stress reduction (www.relaxmc.com), are applications of our healthcare strategy. The paradigm shift in healthcare and energy, added to our expertise in technology commercialization, creates opportunities for CTT to exploit for the benefit of our shareholders."

The non-invasive treatment from the research of CTT client Professor Marineo has already been used with successful results in seven hospitals in Italy on over 2,000 patients suffering from intense drug-resistant pain. The device has received Medical Device CE certification from the European Union as an approved electronic-analgesic apparatus. The treatment is performed by applying surface electrodes to the skin to simultaneously treat multiple pain areas. CTT will be seeking device approvals from the U.S. FDA and other global regulators, as well as signing license agreements for marketing and distribution of the Daeyang produced device in the U.S., European and Asian markets.

Mr. Nano added, "In addition to the pain management and stress reduction technologies, we are aggressively marketing our newly acquired solar panel technology, the UAD tubular-connection, LED portfolio, bone biomaterial, Radio Alert Warning System, and Lupus diagnostic and monitoring technologies. CTT is focused on creating value from our technologies, utilizing our strong sales team and effective global alliances to drive revenue growth, improve profitability and create shareholder value. Our full technology portfolio may be viewed on our website."

About Daeyang E&C, Co., Ltd.

Daeyang E&C, founded in 1979, is a publicly traded company in Korea (KOSDAQ:03303) with a market capitalization of $200 million. With a stated corporate philosophy of "Customer success is equivalent to corporate success," Daeyang is the market leader in its unique product segments. To fulfill the company's principle of returning profit to its customers, Daeyang created the MC Square Scholarship in 1993 with over 1,600 scholarships granted to date. Daeyang manufactures and markets a neuroscience device for increasing study efficiency called MC Square that has been established as a strong consumer brand name in Korea. Daeyang E&C accesses multiple business fields, especially in the IT and biotechnology industries, through the resources available from its affiliate Daeyang Venture Capital Ltd., also of Korea. Daeyang develops these VC business lines in health-related fields based on neuroscience technologies. Visit Daeyang's website: www.daeyangenc.com

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net

Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in Item 1A under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

CONTACT: IR Services, LLC
Johnnie D. Johnson
860-434-2465
[e-mail]
In Asia to:
Seung B. Oh
[e-mail]

[lerchengrund]

Antwort auf Beitrag Nr.: 32.638.640 von lerchengrund am 01.12.07 20:49:50

Das charttechnische Bild hat sich im kurzfristigen Bereich zwar eingetrübt, aber noch ist nichts verloren. Es ist durchaus normal, dass es an solchen Marken zu Kämpfen zwischen Bullen und Bären kommt. Gerade hier werden gerne Fehlsignale generiert, so dass man diese Signale nicht überbewerten darf.
Trotzdem sollten wir nun höchste Vorsicht walten lassen und uns auf eine Konsolidierung einstellen, ohne jedoch in Panik zu geraten.
Noch sind die fundamentalen Grundvoraussetzungen bullish, noch müssen wir lediglich davon ausgehen, dass es eine normale Konsolidierung in einem Aufwärtstrend ist. Ob sich dieses Bild aber ändert, wird erst in den nächsten Tagen / Wochen entschieden.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.137.338 von lerchengrund am 20.05.08 21:16:33

University of Connecticut Health Center and Competitive Technologies Announce NIH Grant for Asthma Study
FARMINGTON, Conn. and FAIRFIELD, Conn., May 19, 2008 (PRIME NEWSWIRE) -- University of Connecticut Health Center and Competitive Technologies, Inc. (AMEX:CTT) announced today that Dr. Eric Secor Jr., assistant professor from the Department of Immunology at the University's School of Medicine in Farmington, has been awarded a multiyear $750,000 K-08 Career Development Award from the National Institutes of Health (NIH) and the National Center of Complementary and Alternative Medicine (NCCAM). Dr. Secor's grant is a continuing study of anti-inflammatory and immunomodulatory effects of bromelain, a natural botanical product, in asthma. This work has originated in association with Dr. Roger Thrall, a prominent asthma researcher and recipient of several NIH grants including his current $1.8 million grant to investigate the mechanisms of allergic asthma. CTT has been providing basic funding for Dr. Secor's research to support his proposal to the NIH.


"The University is extremely pleased with receipt of this NIH grant," said Michael J. Hogan, President of the University of Connecticut. "As the state's premier public research university, we sponsor cutting-edge research that generates innovation, academic advancement, economic growth, and improves the lives of our citizens for generations to come. Dr. Secor's grant represents an ideal cooperation between the University, business and government."

CTT is working with Dr. Secor to develop diagnostic tests for asthma and to determine the applicability of bromelain as a treatment. Dr. Secor's NIH grant states that botanicals with unknown mechanisms of action are widely used for treatment and management of acute and chronic conditions such as allergy and asthma. His study of the effect of botanicals and their extracts on the immune system will help clarify the anti-inflammatory mechanism(s) of action of bromelain. Highlighting the global scope of this field, Dr. Secor gave a presentation on his research at the European Traditional Medicine International Congress held in Vinci, Italy, in October 2007, and he will present this month in Toronto, Ontario.

Dr. Secor stated, "Our laboratory work has demonstrated that bromelain affects inflammatory CD4+ T cells which are vital in immune responses in conditions such as allergy and asthma. These continued studies are crucial to understanding the mechanisms, which are responsible for the anti-allergy effects of botanicals such as bromelain. We look forward to our NIH funded work undergoing the peer review process and being published in the appropriate scientific journals."

"The K-08 Award is extremely prestigious grant and supports our confidence in the importance of the research being conducted by Drs. Secor and Thrall," said Ted Kutrumbos, Business Development Consultant for CTT. "It is another example of our being at the forefront of the paradigm shift to treat individuals with integrative medicine, which combines cutting edge science with traditional medicine."

Asthma, a chronic disease that affects breathing, cannot be cured but can usually be controlled. According to the NIH, asthma affects an estimated 22 million people in the U.S., including about six million children. About half of those affected suffer from allergic asthma.

"We look forward to continuing our work with Dr. Secor," said John B. Nano, CTT's Chairman, President and CEO. "CTT's management team is focused on creating value from technologies, restoring stockholder value by signing new license agreements. We are aggressively marketing the pain management therapy, breast cancer detection test, MC Square stress reduction device (www.relaxmc.com), and solar panel technologies to drive revenue growth, improve profitability and create shareholder value. Our full technology portfolio may be viewed on our website."

About the University of Connecticut Health Center

The University of Connecticut Health Center includes the schools of medicine and dental medicine, the UConn Medical Group, University Dentists, and John Dempsey Hospital. Founded in 1961, the Health Center pursues a mission of providing outstanding health care education in an environment of exemplary patient care, research and public service. To learn more about the UConn Health Center, visit our website at http://www.uchc.edu.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

CONTACT: IR Services, LLC
Johnnie D. Johnson
860 434 2465
[e-mail]

[aktienworker]

@lerchengrund

ich finde Dich ziemlich bescheuert.

überall die gleiche Nachricht reinzukopieren.

tsssssssssss

[lerchengrund]

Antwort auf Beitrag Nr.: 34.153.682 von aktienworker am 22.05.08 19:05:47

und machst du irgentetwas besse?

- aber schau mal mein nachfolgendes postinG


da tut sich was!!!

[lerchengrund]

Antwort auf Beitrag Nr.: 34.154.823 von lerchengrund am 22.05.08 21:39:01

Press Release Source: Competitive Technologies, Inc.


Competitive Technologies Provides Pain Therapy Device to Major Cancer Hospice Center

Thursday May 22, 8:50 am ET


FAIRFIELD, Conn., May 22, 2008 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has provided a pain therapy device to the major cancer hospice center, The Scientific Institute of Romagna for the Study and Treatment of Cancer (IRST). John B. Nano, CTT's Chairman, President and CEO and Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A made the presentation in a ceremony today Thursday, May 22, 2008 in Rome. The device was presented during the Gala Dinner of Pharma Finance 2008 sponsored by the Zangani Investor Community(tm). Prof. Valori highlighted how this pain device known as a ``merciful machine'' will assist terminally ill patients, providing a dignified end of life. The device will be used for pain therapy and for demonstration during the training of staff of other health care centers.
ADVERTISEMENT


CTT has exclusive worldwide distribution rights to its pain therapy device, a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The CTT device has Medical Device CE certification from the European Union allowing European sales and CTT has applied for FDA 510(k) medical device authorization for U.S. sales of the device. The patented device uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin.

``There is no event worse than observing any human being suffer from pain such as from cancer, especially pain that is drug resistant,'' said Mr. Nano. ``We believe there is no other product like ours on the market anywhere in the world today that can successfully treat high intensity oncologic pain resistant to morphine and other drugs.''

Developed in Italy by CTT's client, Prof. Giuseppe Marineo, DSc, MD, the device was brought to CTT through the efforts of Prof. Valori, and assistance from the Zangani Investor Community(tm). CTT partner, GEOMC Co. Ltd. of Korea, formerly Daeyang E&C, is producing the device commercially for worldwide distribution.

``CTT's objective is to commercialize this device worldwide,'' said Mr. Nano. ``Based upon the European CE approval status, we have signed a letter of agreement with a multi-billion-dollar European healthcare company for exclusive European distribution rights. We believe revenues from the device will dramatically exceed those produced by any other technology in our 40-year history, and reach approximately $20 million per year, as the device attains mature market levels.''

About The Scientific Institute of Romagna for the Study and Treatment of Cancer

IRST is a Limited Liability Partnership that forms the core of the integrated oncological network in the Rome Regional Health Care System and provides governance for oncological research in the Region. It provides primary health care for the Forli territory and is an oncological center for secondary and tertiary health care for the whole of the Rome area. Its main aims are to reorganize and rationalize the care and treatment of cancer, to introduce a new organizational and management solution allowing the public and private sectors to work together, and to define and improve the standards of oncological research.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: http://www.competitivetech.net

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.



Contact:
IR Services, LLC
Johnnie D. Johnson
860 434 2465
[e-mail]


--------------------------------------------------------------------------------
Source: Competitive Technologies, Inc.

[aktienworker]

ja, und was soll dass, Posting ist doch schon lange bekannt, habe ja nicht umsonst im Dez. 07 einen Thread eröffnet.

aber das Du gleich in 3 Threads alte News reinkopierst, da frag ich mich schon was das soll.

[lerchengrund]

Antwort auf Beitrag Nr.: 34.155.086 von aktienworker am 22.05.08 22:13:19

die Nachricht ist vom 22. Mai 2008 (!)- also brandaktuell von heute !!!!!!!!!!!!!!!!!!!!!!!

[lerchengrund]

Antwort auf Beitrag Nr.: 34.155.256 von lerchengrund am 22.05.08 22:39:23

auf diesem Wochenverlauf lässt sich weiter aufbauen!